Cometriq 140mg and 80mg
(Cabozantinib)

Indicated for the treatment of adult patients with progressive, unresectable, locally advanced or metastatic medullary thyroid carcinoma.

Manufacturer – Ipsen
Specialty – Oncology
Active principle – Cabozantinib

Request your medicine